GlaxoSmithKline (GSK +0.9%) says study results show its new, once-daily HIV drug matches Merck's...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline (GSK +0.9%) says study results show its new, once-daily HIV drug matches Merck's (MRK +0.1%) twice-a-day treatment in effectiveness. GSK and partner Shionogi say their experimental drug dolutegravir showed non-inferiority to Isentress, or raltegravir, when given for 48 weeks alongside two older types of HIV/AIDS medicines. (also)